Optogenetic RP Therapy Gains RMAT - Summary - MDSpire
From the Journals
Feature

Optogenetic RP Therapy Gains RMAT

Ray Therapeutics secures FDA RMAT designation for its optogenetic retinitis pigmentosa therapy

  • April 29, 2026

  • 2 min

Share

Ray Therapeutics has achieved RMAT designation from the FDA for RTx-015, an optogenetic gene therapy for treating retinitis pigmentosa (RP). This status enhances regulatory interaction and accelerates the therapy's development. RTx-015 aims to restore vision by introducing a light-sensitive protein to retinal cells, allowing them to respond to light regardless of the underlying genetic cause. This approach marks a shift from merely delaying progression to restoring vision, addressing a significant clinical need in ophthalmology, especially for patients with advanced disease.

Original Source(s)

Optogenetic RP Therapy Gains RMAT

  • April 29, 2026

Related Content

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min
Why Smart Eye Surgeons Still Make Bad Growth Decisions

You’re not making poor decisions; you’re being forced to decide without clear, trustworthy data across your patient journey

The New Era of Postoperative Inflammation Management

What surgeons need to know about managing post-cataract inflammation